
Insmed’s New Drug Application for Brensocatib in Bronchiectasis: FDA Declines Advisory Committee Meeting at Present
FDA Reaffirms Priority Review for Insmed’s NDA for Brensocatib, No Advisory Committee Meeting Scheduled Insmed Incorporated, a leading biopharmaceutical company, recently announced that the US Food and Drug Administration (FDA) has reaffirmed the application for their New Drug Application (NDA) for brensocatib as being under priority review. This means that the FDA is giving priority…